{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:12:35Z","timestamp":1786947155412,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundaci\u00f3n Nutrici\u00f3n y Crecimiento"},{"name":"Fondo de Investigaciones Sanitarias"},{"name":"Kyowa Kirin Farmac\u00e9utica S.L.U."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      X-linked hypophosphatemia (XLH) is a hereditary rare disease caused by loss-of-function mutations in\n                      <jats:italic>PHEX<\/jats:italic>\n                      gene leading tohypophosphatemia and high renal loss of phosphate. Rickets and growth retardation are the major manifestations of XLH in children, but there is a broad phenotypic variability. Few publications have reported large series of patients. Current data on the clinical spectrum of the disease, the correlation with the underlying gene mutations, and the long-term outcome of patients on conventional treatment are needed, particularly because of the recent availability of new specific medications to treat XLH.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The RenalTube database was used to retrospectively analyze 48 Spanish patients (15 men) from 39 different families, ranging from 3\u00a0months to 8\u00a0years and 2\u00a0months of age at the time of diagnosis (median age of 2.0\u00a0years), and with XLH confirmed by genetic analysis. Bone deformities, radiological signs of active rickets and growth retardation were the most common findings at diagnosis. Mean (\u00b1\u2009SEM) height was \u2212 1.89\u2009\u00b1\u20090.19 SDS and 55% (22\/40) of patients had height SDS below\u20142. All cases had hypophosphatemia, serum phosphate being \u2212 2.81\u2009\u00b1\u20090.11 SDS. Clinical manifestations and severity of the disease were similar in both genders. No genotype\u2014phenotype correlation was found. Conventional treatment did not attenuate growth retardation after a median follow up of 7.42\u00a0years (IQR\u2009=\u200911.26; n\u2009=\u200926 patients) and failed to normalize serum concentrations of phosphate. Eleven patients had mild hyperparathyroidism and 8 patients nephrocalcinosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study shows that growth retardation and rickets were the most prevalent clinical manifestations at diagnosis in a large series of Spanish pediatric patients with XLH confirmed by mutations in the\n                      <jats:italic>PHEX<\/jats:italic>\n                      gene. Traditional treatment with phosphate and vitamin D supplements did not improve height or corrected hypophosphatemia and was associated with a risk of hyperparathyroidism and nephrocalcinosis. The severity of the disease was similar in males and females.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-01729-0","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T03:02:26Z","timestamp":1614394946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-2283","authenticated-orcid":false,"given":"Enrique","family":"Rodr\u00edguez-Rubio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Gil-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Chocron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"de la Cerda-Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fern\u00e1ndez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"de Lucas-Collantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Luis-Yanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan David","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Ferrando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Ant\u00f3n-Gamero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Carrasco Hidalgo-Barquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angustias","family":"Fern\u00e1ndez-Escribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00ba \u00c1ngeles","family":"Fern\u00e1ndez-Maseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniana","family":"Oliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Ariceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"RenalTubeGroup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"issue":"2","key":"1729_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11154-008-9075-3","volume":"9","author":"M Bastepe","year":"2008","unstructured":"Bastepe M, J\u00fcppner H. Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord. 2008;9(2):171\u201380.","journal-title":"Rev Endocr Metab Disord"},{"issue":"7","key":"1729_CR2","doi-asserted-by":"publisher","first-page":"8349","DOI":"10.1096\/fj.201802007R","volume":"33","author":"R Fuente","year":"2019","unstructured":"Fuente R, Gil-Pe\u00f1a H, Claramunt-Taberner D, Hern\u00e1ndez-Fr\u00edas O, Fern\u00e1ndez-Iglesias \u00c1, Alonso-Dur\u00e1n L, et al. MAPK inhibition and growth hormone: a promising therapy in XLH. FASEB J. 2019;33(7):8349\u201362.","journal-title":"FASEB J"},{"issue":"1","key":"1729_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1471-2350-12-116","volume":"12","author":"M Morey","year":"2011","unstructured":"Morey M, Castro-Feij\u00f3o L, Barreiro J, Cabanas P, Pombo M, Gil M, et al. Genetic diagnosis of X-linked dominant hypophosphatemic rickets in a cohort study: Tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type. BMC Med Genet. 2011;12(1):116.","journal-title":"BMC Med Genet."},{"key":"1729_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bone.2019.01.021","volume":"121","author":"C Zhang","year":"2019","unstructured":"Zhang C, Zhao Z, Sun Y, Xu L, JiaJue R, Cui L, et al. Clinical and genetic analysis in a large Chinese cohort of patients with X-linked hypophosphatemia. Bone. 2019;121:212\u201320. https:\/\/doi.org\/10.1016\/j.bone.2019.01.021.","journal-title":"Bone"},{"key":"1729_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bone.2015.05.040","volume":"79","author":"S Capelli","year":"2015","unstructured":"Capelli S, Donghi V, Maruca K, Vezzoli G, Corbetta S, Brandi ML, et al. Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets. Bone. 2015;79:143\u20139. https:\/\/doi.org\/10.1016\/j.bone.2015.05.040.","journal-title":"Bone"},{"issue":"2","key":"1729_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","author":"F Francis","year":"1995","unstructured":"Francis F, Hennig S, Korn B, Reinhardt R, de Jong P, Poustka A, et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X\u2013linked hypophosphatemic rickets. Nat Genet. 1995;11(2):130\u20136.","journal-title":"Nat Genet"},{"key":"1729_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-017-9408-1","author":"R Fuente","year":"2017","unstructured":"Fuente R, Gil-Pe\u00f1a H, Claramunt-Taberner D, Hern\u00e1ndez O, Fern\u00e1ndez-Iglesias A, Alonso-Dur\u00e1n L, et al. X-linked hypophosphatemia and growth. Rev Endocr Metab Disord. 2017. https:\/\/doi.org\/10.1007\/s11154-017-9408-1.","journal-title":"Rev Endocr Metab Disord"},{"issue":"9","key":"1729_CR8","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00467-012-2103-2","volume":"27","author":"J Gattineni","year":"2012","unstructured":"Gattineni J, Baum M. Genetic disorders of phosphate regulation. Pediatr Nephrol. 2012;27(9):1477\u201387.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1729_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.pcl.2018.09.004","volume":"66","author":"M Bitzan","year":"2019","unstructured":"Bitzan M, Goodyer PR. Hypophosphatemic rickets. Pediatr Clin North Am. 2019;66(1):179\u2013207. https:\/\/doi.org\/10.1016\/j.pcl.2018.09.004.","journal-title":"Pediatr Clin North Am"},{"issue":"21","key":"1729_CR10","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, H\u00f6gler W, Linglart A, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378(21):1987\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"1729_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1530\/EC-19-0481","volume":"9","author":"VV Zhukouskaya","year":"2020","unstructured":"Zhukouskaya VV, Rothenbuhler A, Colao A, Di SC, Kamenick\u00fd P, Trabado S, et al. Increased prevalence of overweight and obesity in children with x-linked hypophosphatemia. Endocr Connect. 2020;9(2):144\u201353.","journal-title":"Endocr Connect"},{"issue":"1","key":"1729_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13052-019-0654-6","volume":"45","author":"F Emma","year":"2019","unstructured":"Emma F, Cappa M, Antoniazzi F, Bianchi ML, Chiodini I, Eller Vainicher C, et al. X-linked hypophosphatemic rickets: An Italian experts\u2019 opinion survey. Ital J Pediatr. 2019;45(1):1\u20137.","journal-title":"Ital J Pediatr"},{"issue":"2","key":"1729_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1203\/01.PDR.0000169983.40758.7B","volume":"58","author":"HY Cho","year":"2005","unstructured":"Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y. A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res. 2005;58(2):329\u201333.","journal-title":"Pediatr Res"},{"issue":"9","key":"1729_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J. 2015;62(9):811\u20136.","journal-title":"Endocr J"},{"issue":"4","key":"1729_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00431-006-0357-z","volume":"166","author":"G Ariceta","year":"2007","unstructured":"Ariceta G, Langman CB. Growth in X-linked hypophosphatemic rickets. Eur J Pediatr. 2007;166(4):303\u20139.","journal-title":"Eur J Pediatr"},{"key":"1729_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15:435\u201355.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"1729_CR17","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD, Portale AA, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383\u201393.","journal-title":"J Bone Miner Res"},{"key":"1729_CR18","unstructured":"Renaltube. http:\/\/renaltube.com\/en\/"},{"issue":"5","key":"1729_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding KR. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"8","key":"1729_CR20","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1210\/jcem.86.8.7761","volume":"86","author":"IA Holm","year":"2001","unstructured":"Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT, et al. Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2001;86(8):3889\u201399.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1729_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen S, Johansson S, R\u00e6der H, Bjerknes R. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol. 2016;174(2):125\u201336.","journal-title":"Eur J Endocrinol"},{"key":"1729_CR22","doi-asserted-by":"publisher","first-page":"153892","DOI":"10.1016\/j.metabol.2019.03.009","volume":"103","author":"A Rothenbuhler","year":"2020","unstructured":"Rothenbuhler A, Schnabel D, H\u00f6gler W, Linglart A. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Metabolism. 2020;103:153892. https:\/\/doi.org\/10.1016\/j.metabol.2019.03.009.","journal-title":"Metabolism"},{"issue":"7","key":"1729_CR23","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, et al. A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Min Res. 2011;26(7):1381\u20138.","journal-title":"J Bone Min Res"},{"key":"1729_CR24","unstructured":"Ensembl. https:\/\/www.ensembl.org\/Homo_sapiens\/Gene\/Summary?db=core;g=ENSG00000102174;r=X:22032325-22251310"},{"key":"1729_CR25","unstructured":"Endrocrinoped. http:\/\/www.webpediatrica.com\/endocrinoped\/antropometria.php"},{"key":"1729_CR26","unstructured":"WHO. https:\/\/www.who.int\/nutgrowthdb\/about\/introduction\/en\/index5.html"},{"key":"1729_CR27","unstructured":"Servicio de Bioqu\u00edmica Cl\u00ednica (AGC-Laboratorio de Medicina). Hospital Universitario Central de Asturias. Valores bioqu\u00edmica HUCA. Biblioteca De Pruebas Bioquimicas. 2013."}],"updated-by":[{"DOI":"10.1186\/s13023-021-01786-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000}}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01729-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01729-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01729-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T08:09:30Z","timestamp":1627632570000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01729-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1729"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01729-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-37967\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-37967\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-37967\/v2","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"25 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13023-021-01786-5","URL":"https:\/\/doi.org\/10.1186\/s13023-021-01786-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients information has been processed via RenalTube database where patients signed their consent to participate in scientific studies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients or parents signed consent for publication of their data through RenalTube consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study has been partially funded by Kyowa Kirin Farmac\u00e9utica S.L.U. This company produces the drug Crysvita\u00ae (burosumab). Nevertheless, no patients in this study had been or were being treated with burosumab at the time of data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}